Ivermectin as a therapeutic alternative in neurocysticercosis that is resistant to conventional pharmacological treatment;Ivermectina como alternativa terapéutica en neurocisticercosis resistente al tratamiento farmacológico convencional

Revista de Neurologia

Volumn 46, Issue 11, 2008, Pages 671-674

  Diazgranados Sánchez, Jesús Alberto ^a   Barrios Arrazola G ^b   Costa, J L ^e   Burbano Pabon, J ^c   Pinzon Bedoya J ^d  

^a CENTRO MÉDICO IMBANACO   (Colombia)

^b Centro Médico de Cali   (Colombia)

^c Resonancia de Occidente   (Colombia)

^d UNIVERSIDAD LIBRE   (Colombia)

^e Hospital of Erie   (United States)

Author keywords

Albendazole; Immature parasite; Immunology; Ivermectin; Neurocysticercosis; Resistance

Indexed keywords

ALBENDAZOLE; CHLORIDE CHANNEL; IVERMECTIN; PHENYTOIN; PRAZIQUANTEL; VALPROIC ACID;

ADULT; AGED; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; CLONIC SEIZURE; COMBINATION CHEMOTHERAPY; CYST; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FILARIASIS; HUMAN; IMMUNE RESPONSE; MALE; MULTIPLE CYCLE TREATMENT; NEUROCYSTICERCOSIS; SINGLE DRUG DOSE; STRONGYLOIDIASIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WORM INFECTION;

EID: 45249093462     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4611.2007640     Document Type: Article

References (26)

1. Wallin M, Kurtzke J. Neurocysticercosis in the United States. Neurology 2004; 63: 1559-64.
2. García H, González A, Tsang V, Gilman R. Neurocysticercosis: some of the essentials. Practical Neurology 2006; 6: 288-97.
3. Mas-Sesé G, Vives-Piñera I, Fernández-Barreiro A, Martínez-Lage J F, Martínez-Salcedo E, Alarcón-Martinez H, et al. Estudio descriptivo de neurocisticercosis en un hospital terciario. Rev Neurol 2008; 46: 194-6.
4. Alarcón F. Neurocisticercosis: etiopatogenia, manifestaciones clínicas, diagnóstico y tratamiento. Rev Neurol 2006; 43 (Supl 1): S93-100.
5. Carpio A. Neurocysticercosis: an update. Lancet Infect Dis 2002; 2: 51-62.
6. Nash T, Singh M, White A, Rafshekhar V, Loeb JA, Proaño JA, et al. Treatment of neurocysticercosis. Neurology 2006; 67: 1120-7.
7. Serpa JA, Yancey LS, White AC Jr. Advances in the diagnosis and management of neurocysticercosis. Expert Rev Anti Infect Ther 2006; 4: 1051-61.
8. Del Brutto OH. Neurocysticercosis. Semin Neurol 2005; 25: 243-51.
9. Del Brutto OH, Roos KL, Coffey CS, García HH. Meta-analysis: cysticidal drugs for neurocysticercosis -albendazole and praziquantel. Ann Intern Med 2006; 145: 43-51.
10. García HH, Pretel EJ, Gilman RH, Martínez M, Moviton LH, Del Brutto OH, et al. A trial of antiparasitic treatment to reduce the rata of seizure due to cerebral cysticercosis. N Engl J Med 2004; 350: 249-58.
11. Sotelo J, Del Brutto O, Penagos P, Escobedo F, Torres B. Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis. J Neurol 1990; 11: 69-72.
12. García HH. Diagnosis treatment and control of Taenia solium cisticercosis. Curr Opin Infect Dis 2003; 16: 411-9.
13. Meinking TL, Taplin D, Hermida JL, Pardo R, Kerdel FA. The treatment of scabies with ivermectin. N Engl J Med 1995; 333: 26-30.
14. Victoria J. Uso de ivermectina en niños. Dermatol Pediatr Lat 2003; 1: 61-5.
15. Campbell WC. Ivermectin and abamectin. New York: Springer; 1989.
16. Omura S. Ivermectin: 25 years and still going strong. Int J Antimicrob Agents 2008; 31: 91-8.
17. Steel C, Luján-Trangay A, González-Peralta C, Zea-Flores G, Nutman TB. Immunologic responses to repeated ivermectin treatment in patients with onchocerciasis. J Infect Dis 1991; 164: 581-7.
18. Knab J, Darge K, Büttner DW. Immunohistological studies on macrophages in lymph nodes of onchocerciasis patients after treatment with ivermectin. Trop Med Int Health 1997; 2: 1156-69.
19. Soboslay PT, Dreweck CM, Hoffmann WH, Lüder CG, Heuschkel C, Görgen H, et al. Ivermectin-facilitated immunity in onchocerciasis. Reversal of lymphocytopenia, cellular energy and deficient cytokine production after single treatment. Clin Exp Immunol 1992; 89: 407-13.
20. Akuffo H, Maasho K, Lavebratt C, Engström K, Britton S. Ivermectin-induced immunopotentiation in onchocerciasis: recognition of selected antigens following a single dose of ivermectin. Clin Exp Immunol 1996; 103: 244-52.
21. Zahner H, Schmidtchen D, Mutasa JA. Ivermectin-induced killing of microfilariae in vitro by neutrophils mediated by NO. Exp Parasitol 1997; 86: 110-7.
22. Semnani RT, Keiser PB, Coulibaly YI, Keita F, Diallo AA, Traore D, et al. Filaria-induced monocyte dysfunction and its reversal following treatment. Infect Immun 2006; 74: 4409-17.
23. Carod-Artal FJ. Ictus de causa infecciosa en el trópico. Rev Neurol 2007; 44: 755-63.
24. Erdo SL. Peripheral GABAergic mechanisms. Trends Pharm Sci 1985; 6: 205-8.
25. Alam S, Laughton DL, Walding A, Wolstenholme AJ. Human peripheral blood mononuclear cells express GABA. A receptor subunits. Mol Immunol 2006; 43: 1432-42.
26. García HH, González AE, Evans CAW, Gilman RH. Taenia solium cisticercosis. Lancet 2003; 16: 547-56.